SecBot SecBot
8-K ·Filed May 7, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001104659-26-056783
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

No revenue or guidance provided; the stock will trade on upcoming catalysts (CIRRUS-HCM data, GRAND CANYON results). Monitor for Phase 2 HCM data in Q2 2026 and cash runway - current $499.6M should fund operations into late 2026.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.58
T+0 close · May 7, 2026 · via day close
Latest settled
+7.87%
T+60 · $38.38
Vs SPY
+4.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $35.58entry
  2. T+1 · 6mo ago −0.73%α −1.56% · $35.32
  3. T+5 · 6mo ago −5.12%α −6.62% · $33.76
  4. T+20 · 6mo ago +1.77%α −1.37% · $36.21
  5. T+60 · 4mo ago +7.87%α +4.04% · $38.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.

Key Financial Metrics

EPS
−$0.46
est −$0.48 · +4.2%
Rating
beat

Key Facts

  • Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
  • Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
  • R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
  • Net loss widened to $49.0M from $40.8M in Q1 2025
  • Positive long-term sevasemten data showing functional stabilization up to 3.5 years in Becker MD
  • CIRRUS-HCM Phase 2 12-week data expected Q2 2026; GRAND CANYON pivotal results Q4 2026

Financial Impact

No revenue; net loss increased ~20% YoY. Cash burn $30.5M during Q1 2026.

net losscashR&D expenses

Risk Factors

  • Clinical trial failures could impair stock significantly; GRAND CANYON and CIRRUS-HCM are binary events.
  • Cash burn rate increasing; may require financing within 12-18 months.
  • Pre-revenue biotech with no approved products - volatility expected.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-056783
Document: tm2613489d1_8k.htm0001104659-26-056783
Document: 0001104659-26-056783-index-headers.html0001104659-26-056783
Document: 0001104659-26-056783-index.html0001104659-26-056783
Document: 0001104659-26-056783.txt0001104659-26-056783
8-K Data (Synthetic)0001104659-26-056783

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026